Harvard Bioscience Q2 revenue rises on telemetry demand, lifts 2026 outlook

Harvard Bioscience

11/08/2026 12:12

Overview
Life science technology developer's Q2 revenue grew 11% yr/yr to $22.7 mln
Adjusted EBITDA for Q2 rose to $1.7 mln from $1.5 mln last year
Company raised full-year 2026 revenue growth guidance to 3%-5%

Outlook
Harvard Bioscience sees Q3 revenue of $21.0 mln to $22.6 mln
Company raises 2026 revenue growth guidance to 3%-5% yr/yr
Company expects 2026 adjusted gross margin of 57%-59%

Result Drivers
DEMAND AND ENVIRONMENT - Co said Q2 growth reflected stronger demand and improved environment across key customer channels, per CEO John Duke
CMT AND TELEMETRY TRACTION - Co cited solid commercial traction in telemetry and cellular and molecular technology products, driven by AAA and electroporation businesses
CHINA AND PRODUCT MIX - Outperformance in CMT products and China contributed to slight mix impact on adjusted gross margin

Company press release: ID:nGNXbcD08n

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$22.73 mln
$21.45 mln (2 Analysts)
Q2 Net Loss
 
$2.91 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Harvard Bioscience Inc is $6.00, about 6.1% below its August 10 closing price of $6.39

Reuters Recommended Reads
Aug 10 - Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Aug 11 - Switzerland's Tecan posts higher H1 sales, backs outlook
Aug 10 - Mesa Labs Q1 revenue rises as calibration, biopharma units grow

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)